Treatments were well tolerated and significantly decreased EMT, reduced the activity of prometastatic/proinflammatory transcription factors GATA binding protein (GATA)-1, GATA-2, EGR3 and STAT3, decreased tumor-infiltrating monocytes, increased tumor-infiltrating B cells, abrogated presurgical increases in serum IL-6 and C-reactive protein (CRP) levels, abrogated perioperative declines in stimulated IL-12 and IFNγ, mobilized CD16− “classical” monocytes, and enhanced expression of CD11a in circulating natural killer cells [325]. The gene discussed is GATA2; the disease is neoplasm.